背景:白血病,一种血细胞癌,根据受影响的白细胞类型(淋巴细胞或髓样细胞)和疾病进展(急性或慢性)进行分类。在2020年,它在全球诊断最多的癌症中排名第15位,在癌症相关死亡中排名第11位。474,519例新病例和311,594例死亡(GLOBOCAN2020)。对白血病发展机制的研究可能导致新的治疗方法。泛素特异性蛋白酶(USP),一个去泛素化酶家族,在各种生物过程中发挥关键作用,同时具有肿瘤抑制和致癌功能,尽管仍然需要全面的了解。
目的:本系统综述旨在全面综述泛素特异性蛋白酶如何参与不同类型白血病的发病机制。
方法:我们系统地搜索了MEDLINE(通过PubMed),Scopus,根据系统评价和荟萃分析指南(PRISMA)的首选报告项目和WebofScience数据库,以确定专注于USP在白血病中的作用的相关研究。从选定的文章中提取数据,合成,并组织起来对主题进行连贯的概述。
结果:该综述强调了USP在染色体畸变中的关键作用,细胞增殖,分化,凋亡,细胞周期调节,DNA修复,和抗药性。USP活动显著影响白血病进展,抑制,和化疗敏感性,建议个性化的诊断和治疗方法。泛素特异性蛋白酶也调节基因表达,蛋白质稳定性,复杂的形成,组蛋白去泛素化,和蛋白质在特定白血病细胞类型中的重新定位。
结论:诊断,预后,与泛素特异性蛋白酶(USP)相关的治疗意义具有重要的前景和改变白血病管理的潜力,最终改善患者预后。
BACKGROUND: Leukemia, a type of blood cell cancer, is categorized by the type of white blood cells affected (lymphocytes or myeloid cells) and disease progression (acute or chronic). In 2020, it ranked 15th among the most diagnosed cancers and 11th in cancer-related deaths globally, with 474,519 new cases and 311,594 deaths (GLOBOCAN2020). Research into leukemia\'s development mechanisms may lead to new treatments. Ubiquitin-specific proteases (USPs), a family of deubiquitinating enzymes, play critical roles in various biological processes, with both tumor-suppressive and oncogenic functions, though a comprehensive understanding is still needed.
OBJECTIVE: This systematic review aimed to provide a comprehensive review of how Ubiquitin-specific proteases are involved in pathogenesis of different types of leukemia.
METHODS: We systematically searched the MEDLINE (via PubMed), Scopus, and Web of Science databases according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines (PRISMA) to identify relevant studies focusing on the role of USPs in leukemia. Data from selected articles were extracted, synthesized, and organized to present a coherent overview of the subject matter.
RESULTS: The review highlights the crucial roles of USPs in chromosomal aberrations, cell proliferation, differentiation, apoptosis, cell cycle regulation, DNA repair, and drug resistance. USP activity significantly impacts leukemia progression, inhibition, and chemotherapy sensitivity, suggesting personalized diagnostic and therapeutic approaches. Ubiquitin-specific proteases also regulate gene expression, protein stability, complex formation, histone deubiquitination, and protein repositioning in specific leukemia cell types.
CONCLUSIONS: The diagnostic, prognostic, and therapeutic implications associated with ubiquitin-specific proteases (USPs) hold significant promise and the potential to transform leukemia management, ultimately improving patient outcomes.